Barbara Klughammer
Roche (Switzerland) · 81 works · 4,313 citations · h-index 24
Top works
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- The functioning of the CO2 concentrating mechanism in several cyanobacterial strains: a review of general physiological characteristics, genes, proteins, and recent advances
- Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
- The involvement of NAD(P)H dehydrogenase subunits, NdhD3 and NdhF3, in high‐affinity CO 2 uptake in Synechococcus sp. PCC7002 gives evidence for multiple NDH‐1 complexes with specific roles in cyanobacteria
- A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
- Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
- The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
- Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study
- Fast Induction of High-Affinity HCO3− Transport in Cyanobacteria1
- Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C).
- Inactivation by gene disruption of 2‐cysteine‐peroxiredoxin in Synechocystis sp. PCC 6803 leads to increased stress sensitivity
- Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
- Pooled analysis of clinical outcome for EGFR TKI ‐treated patients with EGFR mutation‐positive NSCLC
- A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
- Tissue sampling in lung cancer: A review in light of the MERIT experience
- Random Insertional Mutagenesis Used in the Generation of Mutants of the Marine Cyanobacterium Synechococcus sp. Strain PCC7002 With an Impaired CO2 Concentrating Mechanism
- A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer